



2<sup>nd</sup> June 2016

BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400001

National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/1, G Block,  
Bandra Kurla Complex  
Bandra (East), Mumbai 400051

Scrip Code: 500674

Scrip Code: SANOFI

Dear Sirs,

**Re: Press Release**

We enclose herewith a Press Release, the contents of which are self-explanatory.

Thanking you,

SANOFI INDIA LIMITED

A handwritten signature in blue ink, appearing to read "K. Subramani", is written over the printed name.

K.SUBRAMANI  
COMPANY SECRETARY

Encl:a/a



## Aditya Narayan elected as Sanofi India Limited's Chairman of the Board of Directors

**Mumbai – June 2, 2016** - Sanofi India Limited (SIL) announced the election of Mr. Aditya Narayan as the Chairman of the Board of Directors.

*"Sanofi India Limited is privileged to have Mr. Aditya Narayan as Chairman of the Board of Directors", said Dr. Shailesh Ayyangar, Managing Director – Sanofi India Limited. "For over 60 years, Sanofi India has played the role of a committed and responsible company by making world-class medicines accessible in India, and meeting the challenges of our nation's growing disease burden. Sanofi India welcomes Mr. Narayan, with his commendable track record as a corporate leader, to guide it through the emerging complexities in the Indian pharmaceutical environment."*

Commenting on his new role, **Aditya Narayan, Chairman, Sanofi India Limited**, said, *"Sanofi India Limited has a superb track record of building strong pharmaceutical brands, several of which are now household names. Its world class manufacturing facilities and ethical marketing practices enjoy a reputation for excellence in serving its growing customers in India and overseas. It is a privilege for me to have been entrusted with the role of the Chairman of the Board of Directors of Sanofi India Limited and I look forward to the support of all its stakeholders in discharging my responsibilities."*

Aditya Narayan, 64, has rich experience in industry for over 40 years. He served ICI Limited, now Akzo Nobel India Limited, for about 30 years across diverse functions and businesses. He was its Managing Director during 1996-2003 and then its non-executive Chairman over 2003 - 2010. Over 2005-2009, he was the President and CEO of BHP Billiton India. He has also served on a number of other Boards. Presently, he is an Independent Director of Hindustan Unilever Limited, Linde India Limited and Chambal Fertilizers and Chemicals Limited.

Sanofi India Limited (SIL) is listed on the BSE Limited and National Stock Exchange of India Limited. The parent company, Sanofi has 60.4% equity stake in this legal entity. The Company's portfolio includes pharmaceuticals and consumer healthcare products. Within pharmaceuticals, Sanofi India has a strong presence in diabetes, being the only company with a balanced oral and insulin portfolio.

### About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris (EURONEXT: [SAN](#)) and in New York (NYSE: [SNY](#)).

## **Sanofi Forward-Looking Statements**

*This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.*

---

### **Contact:**

#### **Media Relations**

Aparna Thomas

Tel. : +91 22 2803 2169

[aparna.thomas@sanofi.com](mailto:aparna.thomas@sanofi.com)